|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Alzheimer Disease | |||||
| 2 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Delirium, Dementia, Amnestic, Cognitive Disorders | |||||
| Dementia | |||||
| Mental Disorders | |||||
| Nervous System Diseases | |||||
| Neurodegenerative Diseases | |||||
| Tauopathies | |||||
| 3 | Interventions listed in this trial | ||||
| Rofecoxib | |||||
| Naproxen | |||||
| 4 | More general drug interventions related to this trial | ||||
| Analgesics | |||||
| Analgesics, Non-Narcotic | |||||
| Anti-Inflammatory Agents | |||||
| Anti-Inflammatory Agents, Non-Steroidal | |||||
| Antirheumatic Agents | |||||
| Central Nervous System Agents | |||||
| Cyclooxygenase 2 Inhibitors | |||||
| Cyclooxygenase Inhibitors | |||||
| Enzyme Inhibitors | |||||
| Gout Suppressants | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Sensory System Agents | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| National Institute on Aging (NIA) | |||||